×

Intellectual Property Patents

  • Mohawk Tribe sues Microsoft, Amazon for patent infringement

    CNBC's Meg Tirrell reports on the latest patent lawsuits from the Saint Regis Mohawk Tribe.

  • Oct 18- A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm. The Saint Regis Mohawk Tribe was assigned the patents by SRC Labs LLC in August, in a deal intended to use the tribe's sovereign status to shield them from administrative...

  • Oct 18- A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm. The Saint Regis Mohawk Tribe was assigned the patents by SRC Labs LLC in a deal intended to use the tribe's sovereign status to shield them from administrative review.

  • Saint Regis Mohawk Tribe Chief Eric Thompson next to the Saint Lawrence River in upstate New York. The tribe aims to diversify its economy through patent partnerships with technology companies.

    The tribe is a co-plaintiff with SRC Labs, which claims its data processing technology patents have been infringed for years.

  • Oct 17- A U.S. judges ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said. In a deal announced last month, Allergan transferred the...

  • Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc.. "What Allergan seeks is the right to continue to enjoy the considerable benefits of the U.S. patent system without accepting the limits that Congress has...

  • Brent Saunders, CEO of Allergan.

    Allergan could now face generic competitors for its dry eye medicine that accounted for more than 10 percent of the company's revenue.

  • Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries Ltd.. The drug generated around $1.5 billion in sales for Allergan last year and accounted for more than 10 percent of the company's revenue. Senator Claire McCaskill...

  • Oct 16- Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan...

  • Oct 16- A U.S. judge on Monday invalidated patents issued to Allergan Plc on its dry eye medicine Restasis, saying they covered ideas that were too obvious to protect. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries...

  • TORONTO, Oct 13- A key attorney executing BlackBerry Ltd's patent licensing strategy has left the company, the second recent departure from the team tasked with making money from the Canadian company's intellectual property. Victor Schubert, who was a licensing director for BlackBerry, told Reuters in a brief LinkedIn message that he was no longer with the...

  • Oct 13- Qualcomm Inc confirmed an earlier report that the chipmaker had filed lawsuits in China, seeking to halt the manufacture and sale of Apple Inc's iPhones in the country. Qualcomm filed the suits in a Beijing intellectual property court, claiming patent infringement and is seeking injunctive relief, a company spokeswoman confirmed on Friday, but did not...

  • Qualcomm CEO Steve Mollenkopf

    Qualcomm filed the suits in a Beijing intellectual property court, claiming patent infringement and is seeking injunctive relief.

  • Oct 12- Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc are still contesting those patents in U.S. District Court in Marshall, Texas. Allergan transferred the...

  • TORONTO/ NEW YORK, Oct 12- BlackBerry Ltd said a licensing deal it signed with low-end Android handset maker BLU Products Inc will bring it recurring revenue, ending a legal dispute over patents that rival Google has asked the U.S. government to revoke. BlackBerry filed two lawsuits against Miami- based BLU in June 2016, part of an effort by the Canadian company to...

  • ZURICH, Oct 12- Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. In 2018 alone, experts estimate the patents will reap $1 billion for Roche and California's City of Hope medical centre, where the...

  • Allergan CEO Brent Saunders is interviewed on the floor of the New York Stock Exchange.

    The group is the latest to call on lawmakers to examine Allergan's controversial patent deal with a Native American tribe.

  • CEO of global pharamceutical company Allergan Brenton Saunders.

    Allergan's unusual deal to shield Restasis from patent challenges has drawn scrutiny from competitors, lawmakers and now a federal judge.

  • Patent Trial and Appeal Board said Neptune Generics LLC and other companies failed to show it was more likely than not that 22 claims underlying the Lilly patent could not be patented. Alimta is Lilly's third biggest-selling drug, accounting for $2.28 billion of the Indianapolis- based company's $21.22 billion of revenue last year, a regulatory filing shows.

  • The ruling from the U.S. Court of Appeals for the Federal Circuit in Washington was a setback for Amgen Inc, which claimed Praluent infringed patents on its rival drug, Repatha, and had won the sales ban after a jury trial. Regeneron shares jumped 4.4 percent to $475.95 on the Nasdaq, while Sanofi shares in Paris rose 0.8 percent. Amgen shares were off 1.5 percent at...